BD (Becton, Dickinson and Company) announced its fiscal 2025 third quarter results on August 7, 2025, reporting total revenues of $5.509 billion. This represents a 10.4% increase as reported and 3.0% organic growth year-over-year, with an increased organic growth trajectory in the quarter.
Adjusted diluted earnings per share for Q3 FY25 were $3.68, a 5.1% increase from the prior-year period. This performance was fueled by BD Excellence, the company's operating system driving margin and EPS growth.
BD raised its full-year adjusted EPS guidance to a range of $14.30 to $14.45, reflecting an $0.18 increase and 9.4% growth at the midpoint. The company reaffirmed its organic revenue growth guidance of 3.0% to 3.5% for the full fiscal year.
The company also referenced its July agreement to combine the Biosciences and Diagnostic Solutions business with Waters Corporation, a strategic move expected to create an innovative life science and diagnostic leader. BD remains focused on closing this transaction and realizing the value-creation opportunity for shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.